NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Relay Therapeutics, Inc. (RLAY) Stock Analysis

Relay Therapeutics, Inc. (RLAY) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

RLAY

$18.41

−$0.04 (−0.22%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RLAY with… →

RLAY Key Statistics

As of Oct 21, 2026
Trading
Open
$18.61
Previous Close
$18.45
Day's Range
18.19–19.03
52-Week Range
5.95–21.27
Volume
1.60M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.73
Valuation
Market Cap
$4.03B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
389.80
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.56
Financials (FY)
Revenue (FY)
$15.36M+53.44%
Net Income (FY)
−$276.48M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
219.14M
1-Year Return
+161.51%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
2.75M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, RLAY closed at $18.41, +161.51% over 1 year.

Relay Therapeutics, Inc. (RLAY) has a market capitalization of $4.03B.

In fiscal 2025, RLAY reported revenue of $15.36M.

RLAY Stock Return by Calendar Year

Relay Therapeutics, Inc. (RLAY) return since Jul 2020: what $10,000 became

1 year
$10,000 $26,151
+161.51%
5 years
$10,000 $5,891
−41.09%
Since Jul 2020
$10,000 $5,252
−47.48%

If you had invested $10,000 in Relay Therapeutics, Inc. (RLAY) at the close on July 16, 2020, the earliest close on record here, it would have been worth $5,252 at the close on October 21, 2026: −47.48% in total, −9.77% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+117.61%
2025+105.34%
2024−62.58%
2023−26.31%
2022−51.35%
2021−26.11%
2020 (partial year)+18.57%

As of October 21, 2026.

RLAY Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$15.36M−$276.48M−1,800.6%
2024$10.01M−$337.71M−3,374.7%
2023$25.55M−$341.97M−1,338.7%
2022$1.38M−$290.51M−21,036.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$15.36M—−$302.74M−$276.48M−1,800.6%
2024$10.01M—−$385.67M−$337.71M−3,374.7%
2023$25.55M—−$379.42M−$341.97M−1,338.7%
2022$1.38M—−$310.95M−$290.51M−21,036.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RLAY Valuation vs Biotechnology Median

Median of 608 stocks
MetricRLAYBiotechnology medianvs median
P/S ratio389.8013.3029.3x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Relay Therapeutics, Inc. (RLAY) is capitalised at $4.03B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 202.

The 52-week range on file runs from $5.95 to $21.27. RLAY last closed at $18.41 on October 21, 2026. That is −$0.04 (−0.22%) against the previous close. The latest close sits 209.41% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $15.36M. Against the prior fiscal year total of $10.01M, that is a change of +53.44%. The same year closed with a net loss of $276.48M. Trailing earnings per share are −1.56.

Across the 4 fiscal years on file, revenue moves from $1.38M in 2022 to $15.36M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 389.8. On price-to-sales that is 29.3 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is +161.51%. Across 5 years the annualized return works out at −10.04%. The reported beta is 1.73. Annualized volatility over the trailing 6 years is 76%.

Growth & Income

No dividend is on file for RLAY.

2026 is still running; the total return is +117.61% year to date. The strongest complete calendar year on file is 2025 at +105.34%; the weakest is 2024 at −62.58%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Relay Therapeutics, Inc. (RLAY) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Relay Therapeutics, Inc. RLAY $4.03B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Relay Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Relay Therapeutics, Inc.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Visit website →